Ingersoll Rand (IR) Q2 2026 earnings review
Organic Growth Reverses to Positive, but Core Margins Compress
Ingersoll Rand delivered a strong top-line quarter, with reported revenues up 9% and organic revenue reversing its prior stagnation to grow 4%. The Precision and Science Technologies (P&ST) segment was the star, boasting a 200 bps margin expansion and strong Life Sciences demand. However, the volume recovery didn't fully translate to the bottom line for the core Industrial Technologies and Services (IT&S) segment, where Adjusted EBITDA margins compressed by 180 bps due to pricing challenges in China and growth investments. Management updated FY26 guidance, noting they expect to finish near the high end of the $3.45-$3.57 Adjusted EPS range.
🐂 Bull Case
After quarters of negative or flat organic growth, Q2 organic revenue accelerated to +4% company-wide. Orders are also up 7% organically in P&ST.
P&ST Adjusted EBITDA margin expanded to an impressive 31.5% (+200 bps YoY), driven by IRX execution and low double-digit order growth in Life Sciences.
🐻 Bear Case
Despite 4% organic revenue growth, IT&S Adjusted EBITDA margin decelerated to 26.8% (down 180 bps YoY), highlighting an inability to fully offset inflation with pricing, particularly in China.
Order growth in the IT&S segment was muted (flat organic) due to delayed long-cycle project orders in the European blower and vacuum business, alongside continued Middle East friction.
⚖️ Verdict: ⚪
Neutral to Bullish. The return of organic volume growth is a significant positive that proves the resilience of the portfolio. However, 180 bps of margin compression in the largest segment (IT&S) prevents a clean sweep and requires monitoring.
Key Themes
Organic Revenue Accelerating
After a challenging 2025 characterized by organic revenue declines (-3.4% in 25Q2, -1.3% in 25Q3), Q2 26 organic revenue growth reversed course and accelerated to +4%. This demonstrates that the stabilization management cited in Q1 is converting into actual shipped volume, particularly in North American compressor activity.
IT&S Margins Reversing
A key concern is the divergence between IT&S volume and profitability. Despite segment revenue growing 9% (4% organically), Adjusted EBITDA margin dropped 180 bps YoY to 26.8%. Management explicitly attributed this to the inability to offset inflationary impacts with price, primarily in China, as well as ongoing commercial investments.
P&ST Segment is the Bright Spot
P&ST continues to be a high-quality growth engine. Organic orders were up 7%, fueled by low double-digit growth in Life Sciences and mid-single-digit growth in Precision Technologies. This volume leverage, combined with IRX execution, propelled segment margins up 200 bps to 31.5%.
M&A Flywheel Continues Spinning
Inorganic growth remains a staple driver. IR deployed $110 million to M&A in Q2, including the acquisition of Fox s.r.l. They also announced the signing of Fai Filtri s.r.l. (expected to close in Q4 2026) and a U.S.-based blower manufacturer. These bolt-ons are expected to contribute ~2.5% to full-year revenue growth.
Long-Cycle Project Elongation
While short-cycle compressor activity was healthy, organic order growth in IT&S was stable at roughly flat. This was dragged down by the timing of long-cycle project orders in the blower and vacuum business in Europe, alongside ongoing impacts from the Middle East. Management expects these to recover, but the elongation trend noted in prior quarters persists.
Other KPIs
Generated $269M in Q2 (13.1% margin), up from $210M in the prior year period. Conversion remains robust and provides ample ammunition for the dual-pronged capital allocation strategy: $110M for M&A and $240M for share repurchases in the quarter.
Stable. Leverage remained flat compared to the second quarter of the prior year, despite active M&A and aggressive buybacks. Liquidity sits at a comfortable $3.8 billion, securing the recent Moody's upgrade to Baa1.
Guidance
Accelerating. Implies a healthy trajectory considering 2025 saw organic revenue declines. Guidance assumes +1% to +3% organic growth, +2.5% from M&A, and +1% from currency tailwinds. The revenue phasing remains back-half weighted (1H 48% / 2H 52%).
Accelerating. Management explicitly stated they expect to finish near the high end of this range. The midpoint of $3.51 implies ~5% growth over FY25's $3.34.
Stable. The $2,160M midpoint represents approximately 3% growth over 2025's $2,093.8M. The phasing assumes 1H 46% and 2H 54%, implying significant margin expansion is still required in the second half of the year to hit these targets, especially given the Q2 IT&S margin compression.
Key Questions
IT&S Margin Recovery Bridge
With IT&S margins down 180 bps this quarter primarily due to China pricing and inflation, what specific actions are being taken to recover this margin in H2 to meet the full-year EBITDA guidance?
China Market Dynamics
You noted an inability to offset inflation with price in China. Is this a structural shift in the competitive landscape, or do you view it as a temporary macro headwind?
European Long-Cycle Projects
European blower and vacuum orders were delayed. Are these projects simply shifting to the right, or is there an increased risk of cancellation given the current European macroeconomic backdrop?
Life Sciences M&A Pipeline
Following the impressive double-digit growth in Life Sciences and continued bolt-on M&A, how much runway is left in this specific vertical before valuations become prohibitive?